Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 46

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 46
---
2020 to April 2021, our Senior Vice President of Clinical Operations from January 2018 to August 2020, our Vice President of Clinical Operations from 2013 to 2018 and our Executive Director of Operations from October 2008 to 2013. From May 1996 to September 2008, Ms. Oelschlager served as Director of Clinical Research of Arizona Pulmonary Specialists, where she managed a multi-specialty clinical research department. Ms. Oelschlager has co-authored multiple scientific publications and is a co-inventor of a number of our technologies. Ms. Oelschlager completed her core nursing requirements at Purdue University and holds an A.S. degree in nursing from Indiana Vocational Technical College.

#### Castle Biosciences 2025 Proxy Statement45
| Compensation Discussion 
 and Analysis            |

In the Compensation Discussion and Analysis (“CD&A”) section, we describe the material components of our executive compensation program for our NEOs, whose compensation is set forth in the Summary Compensation Table and other compensation tables contained in this Proxy Statement.

This CD&A provides an overview of our executive compensation philosophy, the objectives of our executive compensation program and each material element of compensation that we provide to our executive officers. In addition, we explain how and why our Compensation Committee arrived at specific compensation policies and decisions involving our NEOs for the year ended December 31, 2024. This CD&A is intended to be read in conjunction with the immediately following tables, which include historical context for certain elements of compensation.

### NAMED EXECUTIVE OFFICERS
Our NEOs for the fiscal year ended December 31, 2024, which consist of our principal executive officer (“PEO”), principal financial officer and our only other executive officers, are:

• Derek J. Maetzold, our President and CEO;

• Frank Stokes, our Chief Financial Officer;

• Tobin W. Juvenal, our Chief Commercial Officer; and

• Kristen M. Oelschlager, our Chief Operating Officer.

### BUSINESS OVERVIEW
Our commercially available proprietary tests focus on answering clinical questions arising during the treatment of:

• Dermatologic cancers — DecisionDx®-Melanoma, DecisionDx®-SCC, and MyPath® Melanoma

• Barrett’s esophagus — TissueCypher® Barrett’s Esophagus Test

#### •

#### Uveal melanoma

#### — DecisionDx®-UM
#### •

#### Mental health diagnoses

#### —